News Pharma Industry

suven: PE Advent completes acquisition of Suven Pharma, appoints new Board and management team

[ad_1]

Private equity firm Advent International on Friday announced the completion of its majority acquisition of Hyderabad-based listed contract development and manufacturing organisation (CDMO) Suven Pharma.

Advent acquired 50.1% stake in Suven at an agreed price of Rs 495/share in December last year a firm promoted Venkat Jasti and his family members for Rs 6,313 crore paying ₹495 per share.

Enhance Your Healthcare Expertise with High-Impact Courses

Offering College Course Website
Indian School of Business ISB Healthcare Management Visit
IIM Kozhikode IIMK Healthcare Management & Analytics Programme Visit

Advent will also launch an open offer for an additional 26% of the company, taking the potential investment to Rs 9589 crore, one of the biggest in the Indian CDMO sector.

The government early this month cleared the acquisition.

The private equity firm on Friday has also announced the new Board of directors and management team for Suven Pharma.

Suven Pharma will be led by a management team comprising Annaswamy Vaidheesh, executive chairman, V Prasada Raju, managing director and Sudhir Kumar Singh, chief executive officer to drive Suven Pharma’s global growth as it aims to become a top CDMO player.Annaswamy Vaidheesh, a pharmaceutical veteran with over 35 years of experience, including as MD of GSK India, and earlier was with J&J Asia Pacific in senior regional leadership positions.Prasada Raju, has over 29 years of experience in the pharmaceutical industry, with leadership roles at Cohance Life Sciences, Granules India Ltd. and Dr Reddy’s Laboratories. Dr Sudhir Kumar Singh, a reputed industry veteran who was the ex-COO at Aragen Life Sciences for more than 10 years, joins as the CEO of Suven Pharma.

“We are delighted to enter the value creation phase of our journey with the appointment of an experienced management team,” said Shweta Jalan, managing partner at Advent International.

“Our new leaders are stalwarts of the industry, and we believe they are the right team to deliver on the ambitious vision we have set out for Suven,” Jalan added.

“These are fascinating times for us as we take on the responsibility of leading Suven Pharma to new frontiers. We aim to leverage our expertise, resources across Advent, and Suven team’s proven capabilities to deliver high-quality services to Suven’s customers worldwide,”
Vaidheesh said.

In addition to the new management team, Suven has appointed an Advisory Council with Venkateswarlu Jasti, founder, Suven Pharma and Suven Lifesciences; Abhijit Mukherjee, Ex-COO of Dr Reddy’s; James Mullen, ex-president and CEO of Patheon and Biogen; and Stefan Stoffel, ex-COO of Lonza.

In terms of the Board of directors, along with Vaidheesh and Raju, Pankaj Patwari, managing director at Advent, will also join the team. Suven will also have three independent directors joining the board K.G Ananthakrishnan, ex-MD MSD India and ex-director general of OPPI, and chairman of PNB; Matangi Gowrishankar, ex-BP global head of Capability Development, and Vinod Rao, ex-global treasurer and head of Investor Relations for Diageo.

Advent plans to foster Suven’s capabilities to help it strive towards becoming one of the leading companies in the CDMO space globally.

[ad_2]

Source link